Abstract
Pregabalin is an anticonvulsant drug that binds to the α2δ (alpha2delta) subunit of the voltage-dependent calcium channel in central nervous system (CNS). Pregabalin decreases the release of neurotransmitters, including glutamate, norepinephrine, substance P and calcitonin gene-related peptide. Purpose of this paper is to offer a qualitative overview of the studies currently available in literature about this drug, examining the effectiveness of pregabalin in its various fields of application. Our analysis, conducted on a final selection of 349 scientific papers, shows that pregabalin may help to reduce pain in diabetic neuropathy, in post-herpetic neuralgia and in some patients affected by fibromyalgia. It is also effective for the treatment of diverse types of seizures and has similar efficacy to benzodiazepines and venlafaxine in anxiety disorder. Moreover, pregabalin may be a therapeutic agent for the treatment of alcohol abuse, in both withdrawal phase and relapse prevention. Possible implications in the treatment of benzodiazepines dependence are emerging, but a potential abuse or misuse of the drug has also been reported. Range of dosage may fluctuate considerably, from 75 mg to 600 mg per day. Further studies are needed to completely understand pregabalin mechanism of action in the different diseases.
Keywords: Abuse, alcohol, anxiety, benzodiazepines, epilepsy, fibromyalgia, neuropathic pain, pregabalin.
Current Pharmaceutical Design
Title:The Potential of Pregabalin in Neurology, Psychiatry and Addiction: A Qualitative Overview
Volume: 19 Issue: 35
Author(s): Giovanni Martinotti, Matteo Lupi, Fabiola Sarchione, Rita Santacroce, Anatolia Salone, Domenico De Berardis, Nicola Serroni, Marilde Cavuto, Maria Signorelli, Eugenio Aguglia, Alessandro Valchera, Felice Iasevoli and Massimo Di Giannantonio
Affiliation:
Keywords: Abuse, alcohol, anxiety, benzodiazepines, epilepsy, fibromyalgia, neuropathic pain, pregabalin.
Abstract: Pregabalin is an anticonvulsant drug that binds to the α2δ (alpha2delta) subunit of the voltage-dependent calcium channel in central nervous system (CNS). Pregabalin decreases the release of neurotransmitters, including glutamate, norepinephrine, substance P and calcitonin gene-related peptide. Purpose of this paper is to offer a qualitative overview of the studies currently available in literature about this drug, examining the effectiveness of pregabalin in its various fields of application. Our analysis, conducted on a final selection of 349 scientific papers, shows that pregabalin may help to reduce pain in diabetic neuropathy, in post-herpetic neuralgia and in some patients affected by fibromyalgia. It is also effective for the treatment of diverse types of seizures and has similar efficacy to benzodiazepines and venlafaxine in anxiety disorder. Moreover, pregabalin may be a therapeutic agent for the treatment of alcohol abuse, in both withdrawal phase and relapse prevention. Possible implications in the treatment of benzodiazepines dependence are emerging, but a potential abuse or misuse of the drug has also been reported. Range of dosage may fluctuate considerably, from 75 mg to 600 mg per day. Further studies are needed to completely understand pregabalin mechanism of action in the different diseases.
Export Options
About this article
Cite this article as:
Martinotti Giovanni, Lupi Matteo, Sarchione Fabiola, Santacroce Rita, Salone Anatolia, Berardis De Domenico, Serroni Nicola, Cavuto Marilde, Signorelli Maria, Aguglia Eugenio, Valchera Alessandro, Iasevoli Felice and Giannantonio Di Massimo, The Potential of Pregabalin in Neurology, Psychiatry and Addiction: A Qualitative Overview, Current Pharmaceutical Design 2013; 19 (35) . https://dx.doi.org/10.2174/13816128113199990425
DOI https://dx.doi.org/10.2174/13816128113199990425 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stem Cells Derived from Human Exfoliated Deciduous Teeth (SHED) in Neuronal Disorders: A Review
Current Stem Cell Research & Therapy Management of Type-1 and Type-2 Diabetes by Insulin Injections in Diabetology Clinics - A Scientific Research Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Medicinal Chemistry Approaches for Glucokinase Activation to Treat Type 2 Diabetes
Current Medicinal Chemistry Contemporary Risk Assessment and Cardiovascular Outcomes in Peripheral Arterial Disease
Cardiovascular & Hematological Disorders-Drug Targets Recent Patents on Novel P2X7 Receptor Antagonists and their Potential for Reducing Central Nervous System Inflammation
Recent Patents on CNS Drug Discovery (Discontinued) Editorial [Hot Topic: Current Approaches to the Treatment of Diabetes (Guest Editor: Stephen L. Gwaltney II)]
Current Topics in Medicinal Chemistry Type 2 Diabetes Mellitus and Invokana: An FDA Approved Drug
Current Diabetes Reviews A Comprehensive Review on Phytochemistry and Pharmacological Effects of Stinging Nettle (Urtica dioica)
Current Traditional Medicine Bone Mineral Density in Type 2 Diabetes Patients with Charcot Arthropathy
Current Diabetes Reviews Identification of GCP II Inhibitors Based on 4-Arylmethyl-3-(4- carboxyphenyl)-5-hydroxyisoxazole Scaffold
Letters in Drug Design & Discovery The Interactions Between Diabetes Mellitus and Myelodysplastic Syndromes: Current State of Evidence and Future Directions
Current Diabetes Reviews Recent Advances in the Treatment of Neurogenic Erectile Dysfunction
Recent Patents on CNS Drug Discovery (Discontinued) Recent Studies on Neural Tube Defects in Embryos of Diabetic Pregnancy: An Overview
Current Medicinal Chemistry T-type Calcium Channels in Health and Disease
Current Medicinal Chemistry Oxidative Stress Genes, Antioxidants and Coronary Artery Disease in Type 2 Diabetes Mellitus
Cardiovascular & Hematological Agents in Medicinal Chemistry PDE5 Inhibitors in Non-Urological Conditions
Current Pharmaceutical Design Editorial [Hot Topic: Therapeutic Potential of Peptide Motifs - Part I (Executive Editor: Jean-Claude Herve)]
Current Pharmaceutical Design Carbohydrate-Based Drugs in the Treatment of Epilepsy, Depression and Other Affective Disorders
Current Topics in Medicinal Chemistry Entry Inhibitors - A New Class of Aids Drugs
Letters in Drug Design & Discovery α-Glucosidase Inhibitory Effect and Antioxidant Activity of the Extracts of Eighteen Plant Traditionally Used in Algeria for Diabetes
Current Enzyme Inhibition